Navigation Links
Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting

Company Conference Call Scheduled for Friday, May 4, at 9:00 a.m. Eastern Time to Discuss Data

SAN FRANCISCO, May 03, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that new data from the mild and moderate subgroups of Alzheimer's disease patients in the Company's six-month Phase 2 efficacy study of Dimebon showed that both subgroups were improved compared with placebo-treated patients on all five efficacy endpoints studied.

The mean drug-placebo differences at week 26 on the ADAS-cog, the study's primary endpoint, were 2.4 and 5.8 points in the mild and moderate populations, respectively. The overall response rate to Dimebon treatment (percentage of treated patients showing improvement or no change on the CIBIC- plus at week 26) was 81 percent; the mild subgroup had an 84 percent response rate (42 percent improvement and 42 percent no change) and the moderate subgroup had a 77 percent response rate (45 percent improvement and 32 percent no change).

The Company will host a teleconference with David Hung, M.D., Medivation's president and chief executive officer, Lynn Seely, M.D., Medivation's chief medical officer, and Rachelle Doody, M.D., Ph.D., lead investigator for the study, on Friday, May 4, at 9 a.m. Eastern time to discuss the data.

"In this six-month trial, Dimebon probably improved the clinical course of both mild and moderate Alzheimer's disease patients compared to placebo, results I believe to be promising," said Dr. Doody, who holds the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, in Houston. "These improvements were seen consistently across all outcome measures -- cognition, behavior and activities of daily living -- as well as in the independent CIBIC-plus, a measure of global function."

"Forty-four percent of Dimebon patients were improved compared to baseline as assessed by the CIBIC-p
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... 24, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... systems, today reported financial results for the first fiscal ... overview: , Revenues of $47.5 million, up 10% ... of $0.21, up 50% over last year,s comparable quarter. ... of $7.2 million, up 20% over last year,s comparable ...
(Date:7/24/2014)... -- Amgen (NASDAQ: AMGN ) today announced that ... July 29, 2014, after the close of the U.S. financial ... with the investment community at 2 p.m. PT. Participating in ... , chairman and chief executive officer, and other members of ... conference call will be simultaneously broadcast over the Internet and ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 Drexel University ... D. Weber, MD, MS, FACP, has been appointed vice dean ... will join Drexel from The Commonwealth Medical College, where she ... dean for clinical affairs, and professor of medicine. , ... Commonwealth Medical College, Weber had a major role in many ...
(Date:7/25/2014)... News) -- Babies seem to learn even before they,re ... women are 34 weeks pregnant, their unborn babies can ... a familiar nursery rhyme, the researchers report. "The ... in the developing fetus," Charlene Krueger, nursing researcher and ... Nursing, said in a university news release. "This research ...
(Date:7/25/2014)... sent patients to designated cardiac receiving centers dramatically increased ... in Arizona, according to a study published online yesterday ... , "We knew lives would be saved if the ... arrest care and we were able to get cardiac ... done for Level 1 trauma patients," said lead study ...
(Date:7/25/2014)... Parkulture is proud to ... parkour instructor, Jared “JJ” Woods, will be competing on ... Ninja Warrior. The show will premiere on local affiliates ... rerun on the new Esquire Network on Tuesday, July ... has been balancing careers as a professional stuntman for ...
(Date:7/25/2014)... 2014 In today’s technological era, every ... supporting devices. This benefits the organization in various ways. ... attacks which can destroy the confidential information and processes ... and Compliance (EGRC) manage and protect the enterprise from ... cause loss in dollars to the comp may. The ...
Breaking Medicine News(10 mins):Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Rhymes Reveal Evidence of Learning in the Womb 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6
... may be the way to make a living, but it ... new study from the Universit de Montral, office-workers have become ... activity may partly explain the rise in obesity. Their findings, ... , may have health implications for the millions of people ...
... , MONDAY, Oct. 4 (HealthDay News) -- Children whose ... brain chemical serotonin because of gene mutations may be ... later in life, Norwegian researchers report. Serotonin ... important role during development, especially in the development of ...
... of chronic diseases to the top of the EU ... Kidney Health , the EU Diabetes Working Group and ... the European Parliament, together with representatives of health professionals and ... these chronic diseases urgently, they threaten the "Europe 2020 strategy", ...
... CHANGES , The use of a nasal continuous positive ... may cause craniofacial changes in adults with obstructive sleep ... Vancouver, BC, Canada, analyzed baseline and follow-up radiographs from ... for a minimum of 2 years. Changes in craniofacial ...
... SAN FRANCISCO Implementing a Medical Home practice model ... provide comprehensive care to more patients, and to offer ... with their doctors, recommendations and reduce emergency room visits ... 4, 2010, at the American Academy of Pediatrics (AAP) ...
... -- A new vaccine added to standard therapy appears to ... the most deadly form of brain cancer, according to a ... University of Texas MD Anderson Cancer Center. The vaccine ... most aggressive form of the disease. "About a third ...
Cached Medicine News:Health News:Is your job making you fat? 2Health News:New Clues to Possible Genetic Basis for ADHD 2Health News:New Clues to Possible Genetic Basis for ADHD 3Health News:Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment 2Health News:Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment 3Health News:Chest news briefs: CPAP may cause facial changes 2Health News:Medical home care approach improves efficiency and care at clinic for low-income families 2Health News:Duke vaccine extends survival for patients with deadly brain cancers 2Health News:Duke vaccine extends survival for patients with deadly brain cancers 3
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... Designed around the patented Interzeag ... 301 sets the trend in ... Ideal for routine screening and ... performance, accuracy and quality of ...
Focus Toric Monthly lenses. All the advantages of Focus Monthly lenses, now available for patients with astigmatism. Recommended for daily wear. Also approved for extended wear (1-7 days)....
Medicine Products: